Klick Health

Integrated Delivery Networks: Shifting HCP storytelling for the new audience

Read More

As integrated delivery networks (IDNs) continue to grow in importance, Pharmas must identify the impact of IDNs on their business model and explore new communication strategies. But where should you start, and what do you need to focus on to be successful? Let’s explore what makes IDNs different than traditional models and how Pharmas can adapt with the changing landscape…

Because IDNs are expansive systems of providers, services, and sites of care that provide healthcare services and (in some cases) health insurance plans, they employ a “strength in numbers” approach focused on creating value — high quality care for lower costs. IDNs are focused on unique priorities compared to the traditional private practices and hospitals; and Pharma companies will need to adjust their strategy to accommodate this approach.

In an effort to influence the products a particular IDN prescribes, Pharma reps need to talk to the decision-makers influencers who choose and advocate for the products that will be available to HCPs within the network — but many IDNs restrict rep access to these influencers. Instead of calling on an HCP in an office or hospital setting, sales reps are increasingly working with hard-to-reach customers that are administrators such as purchasing executives, pharmacy and therapeutics (P&T) committee heads, or a group purchasing organization that buy on behalf of many HCPs.


“If you know one IDN, you know one IDN…”

But no two IDNs are exactly alike, which makes it challenging to develop an approach to properly engage with IDN customers. A few key distinctions between IDNs include:

So what does this mean for Pharma?

Opportunity for Pharmas

It’s time for Pharmas to go beyond the drug. IDN decision-makers are looking for partnerships that support improved outcomes and cost efficiencies, and are willing to engage when Pharmas:

With these needs and interests in mind, Pharmas should consider an approach that is as unique as the IDNs themselves and shift from a traditional HCP sales model to a productive and insight-based, ongoing partnership:

  1. Identify and understand the decision-makers — clinicians, administrators, or both
  2. Arm decision-makers with the most compelling disease state and treatment information that encourages them to get your product included for consideration with P&T committees
  3. Develop an above-brand story that aligns to the customers’ needs, focusing on business and larger clinical impact
  4. Create an ecosystem of touchpoints that supports partnership versus sales, such as value-based care presentations, cost-savings models, and key opinion leader outreach

Understanding the IDN landscape and what makes the model unique allows Pharmas to identify new customers and opportunities. It’s critical for Pharmas to also understand how it impacts the sales model and consider how to reach and engage these customers. The result is a relationship between IDN partners and Pharmas focused on providing therapeutic area expertise and value-based healthcare opportunities.

More About the Author

Diana Nagel

Diana has 10 years of experience working in marketing strategy and analytics -- the majority in pharmaceuticals. She brings a unique understanding of how to deliver innovative solutions, with a trained eye towards measuring business impact.

Go from news to action. Klick Wire

Weekly Digital Health Newsletter

Klick Health will NEVER spam you. Read our privacy policy

Thank you! You're now signed up to get the Klick Wire every week - news from the world of digital health marketing.

Sorry there seems to be a problem. Please try again later.